BR112014006871A2 - fragmento de peptídeo antígeno, composição, métodos para tratar e/ou aliviar e/ou prevenir deficiências ou anormalidades, para produzir placas no cérebro, para induzir uma resposta imune contra proteína, e para produzir uma vacina, e, anticorpo ou uma mistura de anticorpo - Google Patents
fragmento de peptídeo antígeno, composição, métodos para tratar e/ou aliviar e/ou prevenir deficiências ou anormalidades, para produzir placas no cérebro, para induzir uma resposta imune contra proteína, e para produzir uma vacina, e, anticorpo ou uma mistura de anticorpoInfo
- Publication number
- BR112014006871A2 BR112014006871A2 BR112014006871A BR112014006871A BR112014006871A2 BR 112014006871 A2 BR112014006871 A2 BR 112014006871A2 BR 112014006871 A BR112014006871 A BR 112014006871A BR 112014006871 A BR112014006871 A BR 112014006871A BR 112014006871 A2 BR112014006871 A2 BR 112014006871A2
- Authority
- BR
- Brazil
- Prior art keywords
- producing
- antibody
- alleviating
- abnormalities
- vaccine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| USPCT/US2011/052992 | 2011-09-23 | ||
| PCT/US2012/056728 WO2013044147A1 (en) | 2011-09-23 | 2012-09-21 | Vaccine therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014006871A2 true BR112014006871A2 (pt) | 2017-04-04 |
Family
ID=47018510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014006871A BR112014006871A2 (pt) | 2011-09-23 | 2012-09-21 | fragmento de peptídeo antígeno, composição, métodos para tratar e/ou aliviar e/ou prevenir deficiências ou anormalidades, para produzir placas no cérebro, para induzir uma resposta imune contra proteína, e para produzir uma vacina, e, anticorpo ou uma mistura de anticorpo |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20240270829A1 (enExample) |
| EP (1) | EP2758071B1 (enExample) |
| JP (1) | JP6110861B2 (enExample) |
| KR (3) | KR102129220B1 (enExample) |
| CN (2) | CN104039346A (enExample) |
| AU (1) | AU2012312126B2 (enExample) |
| BR (1) | BR112014006871A2 (enExample) |
| CA (1) | CA2811188C (enExample) |
| DK (1) | DK2758071T3 (enExample) |
| EA (1) | EA032494B1 (enExample) |
| ES (1) | ES2712951T3 (enExample) |
| HU (1) | HUE041277T2 (enExample) |
| IL (1) | IL231564A0 (enExample) |
| MX (1) | MX350928B (enExample) |
| MY (1) | MY169574A (enExample) |
| PH (1) | PH12014500657A1 (enExample) |
| PL (1) | PL2758071T3 (enExample) |
| PT (1) | PT2758071T (enExample) |
| SG (1) | SG11201400795UA (enExample) |
| SI (1) | SI2758071T1 (enExample) |
| TR (1) | TR201901846T4 (enExample) |
| WO (1) | WO2013044147A1 (enExample) |
| ZA (1) | ZA201402071B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ630542A (en) | 2012-08-16 | 2017-06-30 | Ipierian Inc | Methods of treating a tauopathy |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| JP2017512751A (ja) | 2014-02-14 | 2017-05-25 | アイピエリアン，インコーポレイティド | タウペプチド、抗タウ抗体、およびそれらの使用方法 |
| CA3118692A1 (en) | 2018-11-06 | 2020-05-14 | Alsatech, Inc. | Cell-based gene therapy for neurodegenerative diseases |
| SG11202112329RA (en) * | 2019-05-21 | 2021-12-30 | Ac Immune Sa | Anti-abeta vaccine therapy |
| KR20250137159A (ko) | 2023-01-26 | 2025-09-17 | 에이씨 이뮨 에스에이 | 항-a베타 백신 요법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9811401A (pt) | 1997-08-28 | 2000-08-29 | Ajay North America E Som Iodo | Processos para proteger uma substância agrìcola contra pestes que são nocivas para a substância agrìcola e para a proteção de uma substãncia agrìcola, e, composição protetora para substâncias agrìcolas |
| AU2003292936A1 (en) | 2002-12-24 | 2004-07-22 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| NZ567324A (en) * | 2003-02-01 | 2009-08-28 | Wyeth Corp | Active immunization to generate antibodies to soluble A-beta |
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| JP4696079B2 (ja) * | 2003-12-17 | 2011-06-08 | ヤンセン アルツハイマー イミュノセラピー | Ａβ免疫原性ペプチド担体結合物およびそれの製造方法 |
| MX2007000998A (es) * | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| KR101152557B1 (ko) * | 2005-12-12 | 2012-09-07 | 에이씨 이뮨 에스.에이. | 치료 백신 |
| NZ581835A (en) * | 2007-06-12 | 2012-09-28 | Ac Immune Sa | Monoclonal anti beta amyloid antibody |
| HUE055739T2 (hu) * | 2009-03-18 | 2021-12-28 | Ac Immune Sa | Eljárás terápiás alkalmazásra |
-
2011
- 2011-09-23 CA CA2811188A patent/CA2811188C/en active Active
- 2011-09-23 KR KR1020197008710A patent/KR102129220B1/ko active Active
- 2011-09-23 KR KR1020137002631A patent/KR20160005380A/ko not_active Ceased
- 2011-09-23 KR KR1020167021791A patent/KR20160099732A/ko not_active Ceased
-
2012
- 2012-09-21 BR BR112014006871A patent/BR112014006871A2/pt not_active Application Discontinuation
- 2012-09-21 EP EP12772616.4A patent/EP2758071B1/en active Active
- 2012-09-21 HU HUE12772616A patent/HUE041277T2/hu unknown
- 2012-09-21 ES ES12772616T patent/ES2712951T3/es active Active
- 2012-09-21 CN CN201280057432.5A patent/CN104039346A/zh active Pending
- 2012-09-21 PT PT12772616T patent/PT2758071T/pt unknown
- 2012-09-21 EA EA201400376A patent/EA032494B1/ru not_active IP Right Cessation
- 2012-09-21 WO PCT/US2012/056728 patent/WO2013044147A1/en not_active Ceased
- 2012-09-21 CN CN201910160828.6A patent/CN109847058A/zh active Pending
- 2012-09-21 JP JP2014532040A patent/JP6110861B2/ja active Active
- 2012-09-21 PH PH1/2014/500657A patent/PH12014500657A1/en unknown
- 2012-09-21 MX MX2014003325A patent/MX350928B/es active IP Right Grant
- 2012-09-21 MY MYPI2014000851A patent/MY169574A/en unknown
- 2012-09-21 TR TR2019/01846T patent/TR201901846T4/tr unknown
- 2012-09-21 SI SI201231487T patent/SI2758071T1/sl unknown
- 2012-09-21 DK DK12772616.4T patent/DK2758071T3/en active
- 2012-09-21 PL PL12772616T patent/PL2758071T3/pl unknown
- 2012-09-21 AU AU2012312126A patent/AU2012312126B2/en active Active
- 2012-09-21 SG SG11201400795UA patent/SG11201400795UA/en unknown
-
2014
- 2014-03-18 IL IL231564A patent/IL231564A0/en active IP Right Grant
- 2014-03-20 ZA ZA2014/02071A patent/ZA201402071B/en unknown
-
2023
- 2023-12-22 US US18/395,150 patent/US20240270829A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014531455A (ja) | 2014-11-27 |
| KR20160005380A (ko) | 2016-01-15 |
| MX2014003325A (es) | 2014-05-21 |
| NZ622653A (en) | 2015-12-24 |
| HUE041277T2 (hu) | 2019-05-28 |
| KR20190035948A (ko) | 2019-04-03 |
| PT2758071T (pt) | 2019-01-11 |
| PL2758071T3 (pl) | 2019-08-30 |
| TR201901846T4 (tr) | 2019-03-21 |
| AU2012312126B2 (en) | 2016-11-10 |
| ES2712951T3 (es) | 2019-05-16 |
| AU2012312126A1 (en) | 2014-03-27 |
| EP2758071A1 (en) | 2014-07-30 |
| MX350928B (es) | 2017-09-26 |
| DK2758071T3 (en) | 2019-02-18 |
| WO2013044147A1 (en) | 2013-03-28 |
| IL231564A0 (en) | 2014-04-30 |
| CA2811188C (en) | 2020-04-28 |
| KR102129220B1 (ko) | 2020-07-02 |
| CN104039346A (zh) | 2014-09-10 |
| EA201400376A1 (ru) | 2014-09-30 |
| ZA201402071B (en) | 2017-08-30 |
| US20240270829A1 (en) | 2024-08-15 |
| EA032494B1 (ru) | 2019-06-28 |
| CA2811188A1 (en) | 2013-03-23 |
| JP6110861B2 (ja) | 2017-04-05 |
| SI2758071T1 (sl) | 2019-01-31 |
| EP2758071B1 (en) | 2018-11-28 |
| KR20160099732A (ko) | 2016-08-22 |
| MY169574A (en) | 2019-04-22 |
| SG11201400795UA (en) | 2014-10-30 |
| PH12014500657A1 (en) | 2014-05-05 |
| CN109847058A (zh) | 2019-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014028476A2 (pt) | fragmento imunogênico de um polipeptídeo, polinucleotídeo isolado, composição farmacêutica imunogênica, métodos para tratar uma infecção, para gerar uma resposta imune em um sujeito, e para imunizar um sujeito | |
| WO2013068563A3 (en) | Antibody molecules having specificity for human ox40 | |
| HUE053720T2 (hu) | ROR-1 fehérje elleni terápiás antitestek és eljárások alkalmazásukra | |
| MX362456B (es) | Anticuerpos y vacunas para utilizarse en el tratamiento de canceres por ror1 y para inhibir la metastasis. | |
| ZA201504952B (en) | Human antibodies to respiratory syncytial virus f protein and methods | |
| PL2917229T3 (pl) | Przeciwciała i ich fragmenty aktywowane przeciwko domenie alfa-3 białka HLA-G, sposoby i środki ich wytwarzania oraz ich zastosowania | |
| IL240689A0 (en) | Production methods for controlling the content of carbon-terminated lysine, galactose and sialic acid in recombinant proteins | |
| MX357965B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar. | |
| EP2701705A4 (en) | SYNTHETIC TOLEROGENIC NANOTRÄGER FOR REDUCING IMMUNE RESPONSES TO THERAPEUTIC PROTEINS | |
| WO2014113490A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
| BR112014006871A2 (pt) | fragmento de peptídeo antígeno, composição, métodos para tratar e/ou aliviar e/ou prevenir deficiências ou anormalidades, para produzir placas no cérebro, para induzir uma resposta imune contra proteína, e para produzir uma vacina, e, anticorpo ou uma mistura de anticorpo | |
| ZA201308461B (en) | Multiple antigen presenting immunogenic composition and methods and uses thereof | |
| IL231894A0 (en) | Compounds and methods for enhancing innate immune responses | |
| PL2787841T3 (pl) | Peptydy beta-laktoglobuliny do leczenia alergii na białko mleka krowiego | |
| SG11201505460WA (en) | Methods for reducing aggregate levels in protein preparations by treatment with thio-heterocyclic cations | |
| MY165499A (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| BR112013018742A2 (pt) | cya-transportador de polipeptídeo(s) e use para induzir tanto as terapias e resposta imunitária profilática | |
| EP3024482A4 (en) | Methods for diagnosing and treating immune disease | |
| LT3173427T (lt) | Antikūnai prieš su inkstais susijusį antigeną 1 ir antigeną surišantys jų fragmentai | |
| BR112012018840A2 (pt) | proteínas recombinantes para uso em vacina, anticorpos contra as ditas proteínas e métodos de diagnósticos e terapêuticos incluindo as mesmas | |
| EP3362793A4 (en) | Method for detecting neutralizing antibodies against recombinant human insulin in human serum | |
| MX2013009529A (es) | Tratamiento de enfermedad de crohn con fistulas. | |
| EP2726102A4 (en) | PROCESSES AND COMPOSITIONS OF PROTEIN ANTIGENES FOR DIAGNOSIS AND TREATMENT OF HERPES SIMPLEX VIRUS TYPES 1 AND 2 | |
| EP3054300A4 (en) | Method for prognosis of the efficacy of oral immunotherapy for the treatment of allergy to proteins in cow's milk | |
| EP3356548B8 (en) | Immunological signatures and parameters predicting therapeutic responses to anti-tnf therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |